AAV2-GDNF gene therapy

Phase 2

AAskBio Inc

AAV2-GDNF gene therapy is one of 47 therapeutic programs targeting Parkinson disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Parkinson DiseaseRecruiting

Parkinson DiseasePhase 2

Recruiting

Competition

Competitive Landscape

165 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Vesicare

Astellas

Phase 3

1 2

Byetta

Mirapex

3 4

Allegra

CChattem

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

1 6

Xifaxan

SSalix

Phase 3

—7

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—8

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

—9

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

—10

Levodopa/carbidopa

Orion Corporation, Orion Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Parkinson Disease

NCT06285643

Clinical

Trials by Indication[1]

Parkinson disease1 trial

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Recruiting·AAskBio Inc·Phase 2·NCT06285643·127 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AAV2-GDNF gene therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AAV2-GDNF gene therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AskBio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAskBio Inc

AAV2-GDNF gene therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News